Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1398-1404

  Carvalho, Sara ^a   Leijenaar, Ralph T H ^a   Velazquez, Emmanuel Rios ^a   Oberije, Cary ^a   Parmar, Chintan ^a   Van Elmpt, Wouter ^a   Reymen, Bart ^a   Troost, Esther G C ^a   Oellers, Michel ^a   Dekker, Andre ^a   Gillies, Robert ^c   Aerts, Hugo J W L ^a,b   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HISTOGRAM; HUMAN; INTENSITY VOLUME HISTOGRAM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METRIC SYSTEM; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PET SCANNER; PRIORITY JOURNAL; TUMOR VOLUME; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; FOLLOW UP; IMAGE ANALYSIS; IMAGE GUIDED RADIOTHERAPY; IMAGE PROCESSING; IMAGE RECONSTRUCTION; METABOLISM; NON SMALL CELL LUNG CANCER; PET-CT SCANNER; RADIATION DOSE ESCALATION; RADIATION ONCOLOGIST; SURVIVAL PREDICTION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; TUMOR BURDEN;

EID: 84884579594     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.812795     Document Type: Article

References (40)

1. Travis WD, Brambilla E, Müller-Hermelink H K, Harris CC. World Health Organization classification of tumours: Pathology and genetics of tumours of the lung, pleura, thymus and heart. Kleihues P, Sobin LH, editors. Lyon, France: IARC Press, International Agency for Research on Cancer;2004
2. Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2013;10:27-40
3. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: Extracting more information from medicaLimages using advanced feature analysis. Eur J Cancer 2012;48:441-6
4. Salminen E, Mac Manus M. Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer. Ann Med 2001;33:404-9
5. Fuss M. S trategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG Positron Emission Tomography (PET). Acta Oncol 2010;49:948-55
6. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 2013;54:19-26
7. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesioNglycolysis in solid tumours. Eur J Nucl Med MoLimaging 2013;40:290-301
8. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, U m SW, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg 2013;257:364-70
9. Soussan M, Chouahnia K, Maisonobe JA, Boubaya M, Eder V, Morere JF, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. Eur J Nucl Med MoLimaging Epub 2013 Jan 11
10. ICRU Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements 1993
11. Oncology MR. Radiotherapy for NSCLC to a Individualized MLD (BRONC MLD). 2010 [updated 2013 April 29]; Available from:http://clinicaltrials.gov/show/NCT00573040
12. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, WillemseNat, et al. The Netherlands protocol for standardisation and quantifi cation of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med MoLimaging 2008;35:2320-33
13. Wahl R L, Jacene H, Kasamon Y, Lodge M A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(SUPPL. 1):122S-150S.
14. Drzymala RE, Mohan R, Brewster L, Chu J, Goitein M, Harms W, et al. Dose-volume histograms. Int J Radiat Oncol Biol Phys 1991;21:71-8
15. Deasy JO, Blanco A I, Clark VH. CERR: A computationaLenvironment for radiotherapy research. Med Phys 2003;30:979-85
16. Aerts HJ, van Baardwijk AA, Petit S F, Offermann C, Loon J, Houben R, et al. Identifi cation of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386-92
17. Kauppi JT, Oksala N, Salo J A, Helin H, Karhumaki L, Kemppainen J, et al. Locally advanceDesophageal adenocarcinoma: Response tOneoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012;51:636-44
18. Velazquez E R, Aerts H J, Oberije C, De Ruysscher D, Lambin P. Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol 2010;49:1033-9
19. Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, et al. Metabolic imaging metrics correlate with survivaLin early stagElung cancer treated with stereotactic ablative radiotherapy. Lung Cancer 2012;78:219-24
20. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med MoLimaging 2010;37:691-8
21. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fl uorine-18 fluorodeoxyglucose positron emission tomography imaging in patients witHadvanced-stage nonsmall-cell lung carcinoma. J Clin Oncol 2008;26:1459-64
22. Vanderhoek M, Perlman SB, Jeraj R. Impact of the defi nition of peak standardized uptake value on quantifi cation of treatment response. J Nucl Med 2012;53:4-11
23. El Naqa I, Grigsby P, Apte A, KidDe, DonnellYe, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 2009;42:1162-71
24. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDGuptake in non-small cell lung cancer PET studies. Eur J Nucl Med MoLimaging 2011;38:1636-47. a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386-92
25. Kauppi JT, Oksala N, Salo J A, Helin H, Karhumaki L, Kemppainen J, et al. Locally advanceDesophageal adenocarcinoma: Response tOneoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012;51:636-44
26. Velazquez E R, Aerts H J, Oberije C, De Ruysscher D, Lambin P. Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol 2010;49:1033-9
27. Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, et al. Metabolic imaging metrics correlate with survivaLin early stagElung cancer treated with stereotactic ablative radiotherapy. Lung Cancer 2012;78:219-24
28. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med MoLimaging 2010;37:691-8
29. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fl uorine-18 fluorodeoxyglucose positron emission tomography imaging in patients witHadvanced-stage nonsmall-cell lung carcinoma. J Clin Oncol 2008;26:1459-64
30. Vanderhoek M, Perlman SB, Jeraj R. Impact of the defi nition of peak standardized uptake value on quantifi cation of treatment response. J Nucl Med 2012;53:4-11
31. El Naqa I, Grigsby P, Apte A, KidDe, DonnellYe, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 2009;42:1162-71
32. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDGuptake in non-small cell lung cancer PET studies. Eur J Nucl Med MoLimaging 2011;38:1636-47. a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386-92
33. Kauppi JT, Oksala N, Salo J A, Helin H, Karhumaki L, Kemppainen J, et al. Locally advanceDesophageal adenocarcinoma: Response tOneoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012;51:636-44
34. Velazquez E R, Aerts H J, Oberije C, De Ruysscher D, Lambin P. Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol 2010;49:1033-9
35. Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, et al. Metabolic imaging metrics correlate with survivaLin early stagElung cancer treated with stereotactic ablative radiotherapy. Lung Cancer 2012;78:219-24
36. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med MoLimaging 2010;37:691-8
37. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fl uorine-18 fluorodeoxyglucose positron emission tomography imaging in patients witHadvanced-stage nonsmall-cell lung carcinoma. J Clin Oncol 2008;26:1459-64
38. Vanderhoek M, Perlman SB, Jeraj R. Impact of the defi nition of peak standardized uptake value on quantifi cation of treatment response. J Nucl Med 2012;53:4-11
39. El Naqa I, Grigsby P, Apte A, KidDe, DonnellYe, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 2009;42:1162-71
40. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDGuptake in non-small cell lung cancer PET studies. Eur J Nucl Med MoLimaging 2011;38:1636-47